Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / EMMLF - OKYO Pharma reaches milestone with first patient screening for dry eye disease trial

EMMLF - OKYO Pharma reaches milestone with first patient screening for dry eye disease trial

OKYO Pharma Corp

(NewsDirect)

OKYO Pharma Ltd CEO Gary Jacob tellsProactive's Stephen Gunnion that the first patient has beenscreened for the phase II trial of OK-101, a treatment for dry eyedisease (DED), marking a significant step for the company.

Jacob says the phase II trials aims to evaluate the drug'sefficacy and safety in DED patients, with top-line data expectedbefore the end of 2023. If successful, he said the phase II assessmentcould also serve as one of the two required phase III studiesnecessary for US Food & Drug Administration (FDA) approval.

Contact Details

Proactive Investors

+1347-449-0879

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: OKYO Pharma Corp
Stock Symbol: EMMLF
Market: OTC
Menu
EMMLF EMMLF Quote EMMLF Short EMMLF News EMMLF Articles EMMLF Message Board
Get EMMLF Alerts

News, Short Squeeze, Breakout and More Instantly...